Literature DB >> 7573368

Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders.

J J Oudejans1, M Jiwa, A J van den Brule, F A Grässer, A Horstman, W Vos, P M Kluin, P van der Valk, J M Walboomers, C J Meijer.   

Abstract

Using RT-PCR analysis of Epstein-Barr virus (EBV) latent gene transcription in EBV-harboring cell lines (JY and RAJI) and in post-transplantation lymphoproliferative disorders (PT-LPDs), we detected transcription of all tested latent genes (EBNA1, EBNA2, LMP1, LMP2A, and BARF0) in all cases, suggesting the presence of similar EBV expression patterns in both PT-LPDs and cell lines. In addition, the detection of immediate early (ZEBRA) and early gene (BHRF1) transcripts in cell lines and PT-LPDs indicates that activation of the virus lytic cycle occurs. To investigate EBV expression patterns at the single-cell level, a combination of immunohistochemistry and RNA in situ hybridization (including double-staining procedures) was used. In the JY and RAJI cell lines, the latency type 3 expression pattern was detected in 80 to 90% of the cells as shown by the co-expression of EBNA2 and LMP1. In contrast, in the three PT-LPDs that could be analyzed by double staining, cells expressing both EBNA2 and LMP1 were rarely detected. A mixture of at least three different cell populations were identified: (1) cells exclusively expressing EBER1/2 and EBNA1 (latency type 1); (2) cells expressing EBER1/2, EBNA1, and LMP1 (latency type 2); and (3) cells expressing EBER1/2, EBNA1, and EBNA2 in the absence of LMP1. Activation of the lytic cycle was observed in a small minority of cells, as demonstrated by detection of ZEBRA and EA-D in all cases and GP350/220 in two cases. Thus, in contrast to EBV-transformed cell lines, the observed EBV gene expression pattern in PT-LPDs reflects a mixture of multiple EBV-harboring subpopulations expressing different subsets of EBV-encoded proteins. These data indicate that the operational definitions of EBV latencies in vitro cannot easily be applied to PT-LPDs but that a continuum of different latency expression patterns can be detected at the single cell level in these lymphomas with, in a small minority of cells, progression to the virus lytic cycle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7573368      PMCID: PMC1871006     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site.

Authors:  J Sample; L Brooks; C Sample; L Young; M Rowe; C Gregory; A Rickinson; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

2.  Complex transcription of the Epstein-Barr virus BamHI fragment H rightward open reading frame 1 (BHRF1) in latently and lytically infected B lymphocytes.

Authors:  P J Austin; E Flemington; C N Yandava; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

3.  Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders.

Authors:  D M Knowles; E Cesarman; A Chadburn; G Frizzera; J Chen; E A Rose; R E Michler
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

4.  Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease.

Authors:  F A Grässer; P G Murray; E Kremmer; K Klein; K Remberger; W Feiden; G Reynolds; G Niedobitek; L S Young; N Mueller-Lantzsch
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

5.  Localization of Epstein-Barr virus-encoded small RNAs by in situ hybridization.

Authors:  J G Howe; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

6.  Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases.

Authors:  N M Jiwa; J J Oudejans; D F Dukers; W Vos; A Horstman; P van der Valk; J M Middledorp; J M Walboomers; C J Meijer
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

7.  Clonal analysis of posttransplant lymphoproliferative disorders, using both episomal Epstein-Barr virus and immunoglobulin genes as markers.

Authors:  M A Kaplan; J A Ferry; N L Harris; J O Jacobson
Journal:  Am J Clin Pathol       Date:  1994-05       Impact factor: 2.493

8.  BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes.

Authors:  J J Oudejans; A J van den Brule; N M Jiwa; P C de Bruin; G J Ossenkoppele; P van der Valk; J M Walboomers; C J Meijer
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

9.  A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1.

Authors:  F Chen; J Z Zou; L di Renzo; G Winberg; L F Hu; E Klein; G Klein; I Ernberg
Journal:  J Virol       Date:  1995-06       Impact factor: 5.103

10.  Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.

Authors:  M Rowe; D T Rowe; C D Gregory; L S Young; P J Farrell; H Rupani; A B Rickinson
Journal:  EMBO J       Date:  1987-09       Impact factor: 11.598

View more
  24 in total

1.  Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.

Authors:  Q Tao; L J Swinnen; J Yang; G Srivastava; K D Robertson; R F Ambinder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

Review 2.  The role of EBV in post-transplant malignancies: a review.

Authors:  P Hopwood; D H Crawford
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

3.  Natural history of primary Epstein-Barr virus infection in children of mothers infected with human immunodeficiency virus type 1.

Authors:  H Jenson; K McIntosh; J Pitt; S Husak; M Tan; Y Bryson; K Easley; W Shearer
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

4.  Activity of the EBNA1 promoter associated with lytic replication (Fp) in Epstein-Barr virus associated disorders.

Authors:  A A Brink; C J Meijer; J M Nicholls; J M Middeldorp; A J van den Brule
Journal:  Mol Pathol       Date:  2001-04

5.  Epstein-Barr virus gene expression in post-transplant lymphoproliferative disorders.

Authors:  M Rowe; G Niedobitek; L S Young
Journal:  Springer Semin Immunopathol       Date:  1998

6.  EBNA expression in Reed-Sternberg like cells in post-transplant lymphoproliferative disorders.

Authors:  R Chetty; S Biddolph; K Gatter
Journal:  J Clin Pathol       Date:  1996-03       Impact factor: 3.411

7.  Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas.

Authors:  A A Brink; D F Dukers; A J van den Brule; J J Oudejans; J M Middeldorp; C J Meijer; M Jiwa
Journal:  J Clin Pathol       Date:  1997-11       Impact factor: 3.411

8.  An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model.

Authors:  Shi-Dong Ma; Xianming Yu; Janet E Mertz; Jenny E Gumperz; Erik Reinheim; Ying Zhou; Weihua Tang; William J Burlingham; Margaret L Gulley; Shannon C Kenney
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

Review 9.  Biology and disease associations of Epstein-Barr virus.

Authors:  D H Crawford
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

10.  IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.

Authors:  Loránd L Kis; Daniel Salamon; Emma K Persson; Noémi Nagy; Ferenc A Scheeren; Hergen Spits; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.